Mitochondrial substrate carrier disorder

Mitochondrial substrate carrier disorder (Orphanet code 254830) is an umbrella classification encompassing a group of rare inherited metabolic diseases caused by defects in mitochondrial substrate carrier proteins. These carrier proteins, located in the inner mitochondrial membrane, are responsible for transporting essential metabolites, cofactors, and nucleotides between the cytoplasm and the mitochondrial matrix. When these transporters are dysfunctional, critical metabolic pathways including oxidative phosphorylation, the citric acid cycle, fatty acid oxidation, and amino acid metabolism can be disrupted. Because this category encompasses multiple distinct transporter defects, the clinical presentation is highly variable. Affected body systems commonly include the nervous system, skeletal muscle, heart, and liver. Key clinical features may include encephalopathy, myopathy, lactic acidosis, developmental delay, seizures, cardiomyopathy, and failure to thrive, depending on the specific carrier protein involved. Onset is typically in infancy or early childhood, though some forms may present later. Treatment is largely supportive and symptom-based, as no curative therapies currently exist for most mitochondrial substrate carrier disorders. Management may include dietary modifications, supplementation with specific vitamins or cofactors (such as thiamine, riboflavin, or carnitine), and avoidance of metabolic stressors such as fasting or illness. Specific subtypes within this group may have more targeted therapeutic approaches. Genetic counseling is recommended for affected families.

Common questions about Mitochondrial substrate carrier disorder